PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488

Wang, Dongchang; Wang, Lingchan; Zhang, Yu; Yan, Zhenfeng; Liu, Leyuan; Chen, Gang

doi:10.1016/j.biopha.2018.12.089

Cited by 50 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also confirmed the overexpression of PYCR1 in two LUAD cell lines and patients' tissues by RT‐qPCR and Western blot assays. Consistent with our findings, PYCR1 was identified to be overexpressed in NSCLC tissues and cells, and its downregulation substantially decreased cell apoptosis 32 . Furthermore, prognostic analysis in Kaplan‐Meier plotter database was performed to identify the role of PYCR1 in LUAD.…”

Section: Discussionsupporting

confidence: 81%

“…Consistent with our findings, PYCR1 was identified to be overexpressed in NSCLC tissues and cells, and its downregulation substantially decreased cell apoptosis. 32 Furthermore, prognostic analysis in Kaplan-Meier plotter database was performed to identify the role of PYCR1 in LUAD. The results elucidated that patients with high PYCR1 expression were associated with low overall survival time in LUAD, indicating that the high expression of PYCR1 had a poor prognosis.…”

Section: Pycr1 Knockdown Affected the Jak/stat Signaling Pathway Inmentioning

confidence: 99%

See 1 more Smart Citation

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

Gao

Luo

Xie

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD), as a form of non‐small cell lung cancer (NSCLC), is the most frequently diagnosed lung cancer worldwide. To date, a few biomarkers have been reported to provide valuable information in guiding LUAD treatment. The aim of our study was to explore the functional role of pyrroline‐5‐carboxylate reductase 1 (PYCR1) in LUAD. Based on Oncomine database, we found that PYCR1 was highly expressed in LUAD tissues. We also confirmed an abnormal increase of PYCR1 expression in LUAD cell lines and patients' tissues. Through Kaplan‐Meier plotter database, we further studied the prognostic values of PYCR1. The outcomes indicated that overexpressed PYCR1 associated with poor prognosis among LUAD patients. To further study the function of PYCR1 in LUAD, cell counting kit‐8, colony‐forming, scratch wound healing, and Transwell assays were conducted. The results suggested that knockdown of PYCR1 curbed cell proliferation, migration, and invasion in LUAD cell lines. Subsequently, we identified 50 top genes positively and negatively correlated with PYCR1 in LUAD, and conducted biological pathway enrichment analysis of these genes. Among those enriched pathways, we selected JAK/STAT signaling pathway for further analysis. The results of Western blot assays revealed that PYCR1 knockdown significantly increased the expression of Bcl‐2 and c‐Myc, and the phosphorylation level of JAK2 and STAT3. Taken together, this study unearthed that PYCR1 knockdown could inhibit tumor growth and affect the JAK/STAT signaling pathway in LUAD. This study may contribute to a better understanding of PYCR1 in LUAD and provide a potential biomarker for cancer prognosis.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Pycr1 Knockdown Affected the Jak/stat Signaling Pathway Inmentioning

confidence: 99%

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

Gao

Luo

Xie

et al. 2020

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…The role of PYCR1 as an oncogene has been demonstrated in several other types of cancers via different molecular mechanisms including regulating p38 MAPK and NF-kB signaling pathway [35][36][37][38].…”

Section: Discussionmentioning

confidence: 99%

“…Besides, PYCR1 can be regulated by microRNAs in some cancers [37][38]. What appeals to us is that despite participation in glucose metabolism, PYCR1 also plays a role in proline metabolism [39] and thus it's worth more comprehensive insights into its molecular functions.…”

Section: Discussionmentioning

confidence: 99%

A signature of glucose metabolism and DNA methylation improves prognostic prediction for urinary bladder cancer

Liu

Sun

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Glucose metabolism and DNA methylation have been previously proved to play important roles in cancers. However, few studies have explored the potential connections between abnormal glucose metabolism and DNA methylation in tumor progression. In this study, we aimed to screen out glucose metabolism-related genes that were DNA methylation associated in order to establish a promising signature for the prognosis of bladder cancer (BLCA).Methods: With transcriptome data of BLCA samples from The Cancer Genome Atlas (TCGA) and methylation data downloaded from TCGA data base 450K microarray, glucose metabolism-related genes that were simultaneously methylation modulated and survival associated were obtained and a prognostic signature was established. Gene set enrichment analysis (GSEA) and weighted gene co-expression network analysis (WGCNA) were performed for identification of gene and pathway enrichment. Two most methylation-related risky genes were selected to conduct functional validations. Results: 18 target genes were identified and the samples were survival-significantly divided into two groups by using the signature. Via multivariate Cox analysis, we considered the signature an independent prognostic factor. Several biological processes and signaling pathways were enriched in the high-risk group according to GSEA results and three modules of genes were identified by WGCNA. We demonstrated that UCHL1 and PYCR1 promoted proliferation, migration and invasion ability of bladder cancer cells. Conclusions: The signature based on the 18 target genes could serve as an independent prognostic factor for urinary bladder cancer patients.

show abstract

“…Manuscript to be reviewed proliferation and apoptosis of NSCLC (Wang et al 2019) . Nonetheless, the role of PYCR1 in invasion and resistance to cisplatin of lung adenocarcinoma migration, has not yet been reported.…”

Section: Introductionmentioning

confidence: 99%

Peer Review #1 of "P5CR1 protein expression and the effect of gene-silencing on lung adenocarcinoma (v0.1)"

2019

View full text Add to dashboard Cite

The present study aimed to investigate the expression of pyrroline-5-carboxylate reductase 1 (P5CR1) protein in lung adenocarcinoma and paracancerous tissues and to explore the effect of silencing the encoding gene PYCR1 on the proliferation, migration, invasion, and cisplatin sensitivity in lung adenocarcinoma cells, thereby providing a novel therapeutic target for the treatment of the disease. Immunohistochemistry staining was used to detect the P5CR1 protein expression in lung adenocarcinoma and paracancerous tissues, and statistical analysis evaluated the correlation between P5CR1 protein expression and gender, age, tissue part, or pathological grade. The CCK8 assay was performed to detect the proliferation and cisplatin sensitivity, while the effect of PYCR1 on the migration and invasion of lung adenocarcinoma cells was detected by scratch test and transwell chamber assay. The findings demonstrated that the P5CR1 protein expression was significantly elevated in lung adenocarcinoma tissues and correlated with the pathological grade, whereas no significant correlation was established between the protein expression and gender, age, or tissue part. Furthermore, after PYCR1 gene silencing, the proliferation and invasion were significantly suppressed, while the sensitivity to cisplatin was significantly enhanced. Therefore, it can be speculated that the PYCR1 gene affects the biological behavior of lung adenocarcinoma and cisplatin resistance, serving as a potential therapeutic target for lung adenocarcinoma.

show abstract

PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488

Cited by 50 publications

References 26 publications

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma

A signature of glucose metabolism and DNA methylation improves prognostic prediction for urinary bladder cancer

Peer Review #1 of "P5CR1 protein expression and the effect of gene-silencing on lung adenocarcinoma (v0.1)"

Contact Info

Product

Resources

About